Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 12, 2020 08:00 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. and Curon Biopharmaceutical Limited Announce an Exclusive Licensing Agreement to Develop and Commercialize Tenalisib, a Dual PI3K Delta and Gamma Inhibitor for Oncology in Greater China

La Chaux-de-Fonds, Switzerland and Shanghai, China. October 12, 2020, Oct. 12, 2020 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S. A. (Rhizen), a Switzerland-based privately held clinical-stage...
December 04, 2018 01:00 ET | Source: Viracta Therapeutics, Inc.

Viracta and Salubris Announce Equity Financing and Partnership to Bring Novel Treatment for Viral-Associated Cancers to China

SAN DIEGO and SHENZHEN, China, Dec. 03, 2018 (GLOBE NEWSWIRE) -- Shenzhen Salubris Pharmaceuticals Co. Ltd. (Salubris, SZSE: 002294) and Viracta Therapeutics, Inc. announced the initial closing of a...
April 29, 2018 18:53 ET | Source: Hoverink Biotechnologies, Inc

LADAVRU® RECEIVES APPROVED FOR PUBLICATON NOTICE FROM THE UNITED STATES PATENT AND TRADEMARK OFFICE (USPTO) HOVERINK BIOTECHNOLOGIES ANNOUNCES.

LOS ANGELES, CA, April 29, 2018 (GLOBE NEWSWIRE) -- Hoverink Biotechnologies, Inc announced today it has received its Notice of publication from the UNITED STATES PATENT AND TRADEMARK OFFICE for...
June 12, 2013 05:08 ET | Source: Rhizen Pharmaceuticals SA

Rhizen Pharmaceuticals S.A. announces a scientific presentation on the therapeutic potential of their lead dual PI3K delta/gamma inhibitor in T-cell Lymphomas at the 18th Congress of European Hematology Association, 13-16 June 2013

La Chaux-de-Fonds, Switzerland, June 12, 2013 (GLOBE NEWSWIRE) -- Rhizen Pharmaceuticals S.A. announces a scientific poster presentation on the therapeutic potential of its novel,...